GOOD MORNING
—
Loading...
PENDING
—
👥
—
Active Patients
Under monitoring
🤖
—
AI Decisions Today
Generated by Rosalie
⏳
—
Pending Review
Awaiting attestation
🚨
—
Critical Alerts
Immediate attention
Patient Queue
Active cases requiring attention
| Patient ID | Diagnosis | Risk | Status | |
|---|---|---|---|---|
| Loading... | ||||
Decision Queue
Rosalie AI · AI reasoning engine · Physician attestation required
Select a decision
Patient Queue
Multi-modal unified state · Outcome-weighted learning · PHI encrypted AES-256-GCM
| Patient ID | Diagnosis | Biomarker | Stage | State Ver. | ECOG | Risk Score | Status | |
|---|---|---|---|---|---|---|---|---|
Loading… | ||||||||
Predictive Modelling Engine
10,000 iterations · Weibull survival · Probabilistic outcomes with confidence intervals
| # | Regimen | Median PFS | CI [95%] | Probability | Tox ≥G3 | Class |
|---|---|---|---|---|---|---|
Running simulation… | ||||||
PFS Comparison
Ranked treatment strategies · Progression-free survival
Simulation Parameters
Patient-specific inputs to rosalie-engine-v2
Provider Coordination Engine
Performance scoring module · max(E[outcome] × provider_score) · rovita.io
Loading…
Rosalie AI — Model-Agnostic Clinical Reasoning & Decision Intelligence Engine
Rosalie AI is designed to operate as an independent, deployable intelligence service across multiple healthcare platforms · rovita.io
🧠
Architecture: RoVita orchestrates workflows · Rosalie AI generates decision intelligence
Rosalie AI is a model-agnostic clinical reasoning and decision intelligence engine powering RoVita. The engine evaluates multiple treatment pathways, generates ranked treatment strategies, and evaluates predicted and observed outcome deviations using continuous outcome intelligence.
🎯
—%
Overall Precision
rosalie-engine-v2
⚡
—
Avg Effectiveness
Outcome-weighted learning
🤝
—%
Agreement Rate
Physician agrees with Rosalie
Rosalie AI API Endpoints
Model-agnostic intelligence layer · Independent deployable service
| Method | Endpoint | Function | Status |
|---|---|---|---|
| GET | /rosalie/analyze/:id | Multi-modal patient data analysis | Active |
| GET | /rosalie/predict/:id | Probabilistic outcome prediction with CI | Active |
| POST | /rosalie/reason | AI reasoning chain generation | Active |
| POST | /rosalie/evaluate | Treatment pathway comparative evaluation | Active |
| GET | /rosalie/metrics | Precision & effectiveness per provider | Active |
| POST | /rosalie/feedback | Outcome-weighted learning update | Active |
Precision & Effectiveness per Provider
Continuous learning · KYC/KYB verified
| Provider | Precision | Effectiveness | Agreement | Cases | VVT |
|---|---|---|---|---|---|
Provider Modules
Modular model-agnostic architecture · FHIR R4 · HL7 v2 · KYC/KYB verified · rovita.io
0 connected
Loading…
Data Pipelines
Multi-modal patient data integration · Continuous learning feed
Loading…
Normalization Stats
FHIR R4 validation · PHI masking · S(t) state updates
💰
—
Pending VVT
Provider incentive credits · off-chain
✔
—
Settled (30d)
Provider coordination credits · XRPL
📊
—
Total Issued
Performance incentive layer · Not payment
VVT Coordination Ledger — XRPL
ViroVira Token · Provider incentive & coordination layer only · NOT a payment mechanism · Fees collected in USDC / fiat
Fee Model
Platform fee structure · Invoice management · Payment status
How the Fee Works
Outcome-linked · Post-settlement · No upfront cost
💰
3% platform fee — charged only on confirmed positive outcomes
No subscription. No upfront cost. RoVita invoices 3% of the confirmed intervention value after XRPL VVT settlement is verified and outcome is confirmed positive. Zero fee on negative outcomes.
3%
Platform Fee Rate
$0
Upfront Cost
POST
Settlement Timing
Fee Trigger Process
Step-by-step from decision to invoice
1
Physician Attestation
Clinician reviews and attests the AI-generated treatment recommendation.
2
Positive Outcome Confirmed
Patient outcome is recorded and confirmed positive via Δ(t) outcome tracking.
3
VVT Settlement on XRPL
ViroVira Token is settled on XRPL ledger confirming the outcome-linked incentive.
4
Invoice Generated
RoVita invoices 3% of confirmed intervention value via bank transfer or ACH. No crypto payment required.
Current Fee Status
Active tenant · MCH-0041 · Memorial Cancer Hospital
| Period | Positive Outcomes | Intervention Value | Platform Fee (3%) | Status |
|---|---|---|---|---|
| Jun 2026 | 4 | $1,680,000 | $50,400 | Pending Settlement |
| May 2026 | 7 | $2,940,000 | $88,200 | Invoiced |
| Apr 2026 | 5 | $2,100,000 | $63,000 | Paid |
Payment Methods
Accepted payment rails for platform fee invoices
🏦
Bank Transfer / ACH
Primary method. NET-30 terms.
📄
Invoice / NET-30
Standard invoicing with 30-day payment terms.
💲
USDC Digital Dollar
ON REQUEST
Stable USD equivalent. No volatility. Same NET-30 terms. Contact billing@rovita.io
ℹ️ Platform fee invoices are issued by RoVita Inc. post-settlement. For billing queries contact billing@rovita.io
Immutable Audit Log
Append-only · 7-year retention · UPDATE and DELETE blocked · All Rosalie AI decisions permanently recorded
| Time | Event | Actor | Resource | Patient | PHI | Type |
|---|---|---|---|---|---|---|
Onboarding Checklist
Enterprise · RMC-0113 · rovita.io
Tenant Info
User Management
Admin console · All changes audit-logged · RBAC enforced
| User | Role | MFA | ||
|---|---|---|---|---|
Services
Microservice health · rovita-platform
| Service | Replicas | CPU | Mem | Status |
|---|
Rosalie AI Thresholds
Decision engine parameters · drag sliders to adjust
CONFIDENTIAL —
Validation metrics are for internal use and investor review only.
Aggregate data only. No visitor PII is displayed here.
👥
—
Total Visitors
Unique registrations
⭐
—
Avg Platform Rating
Out of 5.0
💬
—
Comments Received
Across all views
⏱
—
Avg Session Time
Minutes per visitor
Visitors by Role
Who is evaluating RoVita
Visitors by Country
Geographic reach
Ratings per Dashboard View
Average rating · 1–5 stars · All visitors
Time Spent per View
Average seconds · Session tracking
Visitor Registrations Over Time
Daily signups · Demo interest trend
Overall Rating Distribution
How visitors rate the platform
Recent Feedback
Latest visitor comments · Anonymised
| Time | Role | Country | View | Rating | Comment |
|---|---|---|---|---|---|
Investor Validation Summary
Platform Validation at a Glance
All metrics derived from real visitor interactions with the RoVita demo platform.
Visitor identities are verified at registration. Data available for investor due diligence.
CONFIDENTIAL
This document contains proprietary and confidential information belonging exclusively
to RoVita Inc. It is intended solely for the named recipient. Unauthorised disclosure,
reproduction, or distribution is strictly prohibited. By accessing this material you
agree to maintain strict confidentiality.
Patent pending · © 2026 RoVita Inc.
The Problem
Three structural failures in oncology today
🗂
Fragmented data
A patient's clinical picture is scattered across 4–6 disconnected systems —
EHR, radiology, pathology, genomics, pharmacy. Oncologists manually piece it
together in a 15-minute appointment.
🎯
No ranked alternatives at point of care
There is no system that says: "Here are five treatment options for this specific
patient, ranked by predicted outcome, with the evidence and reasoning behind each."
Decisions remain largely experience-based.
💸
Broken incentives
Providers are paid per activity — consultations, procedures, prescriptions —
regardless of whether the patient improves. No mechanism rewards
consistently better clinical decisions.
The Solution
RoVita fixes all three simultaneously
🔗
S(t) — Unified patient state
RoVita automatically assembles all data sources into a single versioned
patient state via FHIR R4 / HL7 v2. No manual aggregation. Complete
clinical picture in real time.
🧠
Rosalie AI — Ranked strategies with CI
Model-agnostic clinical reasoning engine generates 3–5 ranked treatment
strategies with confidence intervals, predicted PFS, toxicity grade,
guideline alignment, and full reasoning chain. Physician approves every
recommendation — hardcoded, cannot be disabled.
⛓
Δ(t) + VVT — Closed loop incentives
Real outcomes feed back into Rosalie AI via outcome-weighted
learning. Providers earn ViroVira Token only on confirmed positive outcomes.
Platform fee of 3% charged only when patients improve.
Unfair Advantages
What no competitor can replicate quickly
Patent-pending architecture
The combination of S(t) unified state, outcome-weighted learning,
outcome-linked VVT incentives, and model-agnostic Rosalie AI as an integrated
system is novel. Each component exists in research — the integration is the
invention. Proprietary architecture.
Compounding data moat
Every confirmed outcome makes Rosalie AI more accurate for that health
system's patient population. The longer RoVita is deployed, the harder it
is to displace. Unlike most software which depreciates, RoVita appreciates.
The data moat compounds with every patient.
Aligned economics — first in class
3% fee only on positive outcomes. Zero fee on negative outcomes.
No subscription. RoVita makes money only when patients improve.
This is the first outcome-aligned fee model in clinical AI —
a sales argument that reframes every procurement conversation.
Watson failure mode — solved
IBM Watson for Oncology failed ($4B invested, discontinued 2022) because it
had no closed loop — trained on hypothetical cases, could never self-correct.
RoVita's Δ(t) mechanism directly addresses this failure. The architectural
lesson from the biggest AI oncology failure is built into our foundation.
Rosalie AI — independently licensable
Rosalie AI is built as a model-agnostic, independently deployable intelligence
service. It can power other healthcare platforms beyond RoVita — creating a
technology licensing revenue stream and a network effect on outcome data across
the entire Rosalie AI ecosystem.
VVT — verifiable outcome trust layer
ViroVira Token on XRPL creates an immutable, publicly verifiable record
of provider outcomes. When a hospital asks "what is Dr. Kim's actual
outcome track record?" — the VVT ledger provides a tamper-resistant answer.
No competitor has an equivalent trust mechanism.
Market Opportunity
TAM · SAM · SOM · 2026 estimates
TOTAL ADDRESSABLE MARKET
$280B
Global oncology software, AI clinical decision support, and precision medicine
market. Includes EHR oncology modules, genomics, imaging AI, and clinical trials.
CAGR 17.4% · 2024–2030
SERVICEABLE ADDRESSABLE MARKET
$18B
US & EU oncology clinical decision support platforms, AI-assisted treatment
planning, and value-based oncology care arrangements at hospital systems with
50+ oncology beds.
~2,400 target health systems · US + EU
SERVICEABLE OBTAINABLE MARKET
$480M
200 US cancer centres (NCI-designated + major community) over 5 years.
Based on 3% fee model on $10B+ in annual oncology interventions
with 60–65% positive outcome rates.
Year 5 target · 200 health systems onboarded
Global cancer burden:
20M+ new cases/year · $1.16 trillion in annual economic cost
US oncology drug spend:
$82B in 2024 · growing 10%/yr
AI health market:
$45B by 2026 · oncology largest segment
Target Customers
Primary · Secondary · Future
Primary
Health Systems & Cancer Centres
Academic medical centres · NCI-designated comprehensive cancer centres
· Community oncology practices · Integrated health systems
Best fit: 200+ new oncology cases/yr · Major EHR (Epic/Cerner) · Value-based care appetite
Best fit: 200+ new oncology cases/yr · Major EHR (Epic/Cerner) · Value-based care appetite
~2,400 US target accounts · ACV $250K–$2M
Secondary
Physicians & Clinical Teams
Oncologists · Tumour boards · Oncology nurses
· Clinical pharmacists
Value prop: Complete patient picture without 4-system login · AI-ranked alternatives with reasoning · Medical-legal documentation
Value prop: Complete patient picture without 4-system login · AI-ranked alternatives with reasoning · Medical-legal documentation
Champions inside primary accounts · drive adoption
Future
Pharma, Biotech & Payers
Oncology pharma · Biotech clinical trial sponsors
· Payers moving to value-based oncology
Revenue: De-identified outcome data licensing · Rosalie AI licensing · Clinical trial acceleration
Revenue: De-identified outcome data licensing · Rosalie AI licensing · Clinical trial acceleration
Secondary revenue · emerges at scale · no extra product dev
How We Measure Success
Platform metrics · Clinical metrics · Business metrics
Clinical
Positive outcome rate
% of confirmed outcomes where observed ≥ predicted. Target: >60%.
Δ(t) deviation accuracy
Mean absolute error between Rosalie AI prediction and real outcome.
Should decrease over time as model learns.
Physician approval rate
% of Rosalie AI top recommendations approved without override.
High rate = accurate recommendations.
Loop closure rate
% of approved decisions that receive a confirmed outcome.
Measures feedback loop completeness.
Platform
Active patients / tenant
Average active patients on the platform per health system.
Measures integration depth and clinical adoption.
Data source coverage
% of patients with all 4 data sources connected (EHR, genomics,
imaging, pathology). Target: >80% at go-live.
Time-to-recommendation
Median seconds from patient data loaded to Rosalie AI ranked
recommendations displayed. Target: <3 seconds.
VVT settled / month
Total VVT settled on XRPL per month. Proxy metric for
confirmed positive outcomes across the network.
Business
ARR (Annual Recurring Revenue)
3% of positive-outcome intervention value per tenant per year.
Scales linearly with patients and outcomes.
Tenant count & NRR
Number of health systems live. Net Revenue Retention — do tenants
expand as they onboard more patients?
Avg revenue / tenant
Platform fee per health system per year. Benchmark: $250K
for mid-size cancer centre (400 cases/yr, 65% positive rate).
CAC & payback period
Customer acquisition cost and months to recover it. Target:
<12-month payback at steady state.
Layer 1
RoVita
Orchestration layer. Assembles S(t), routes to Rosalie AI, enforces physician
approval, manages VVT and payment flows.
"RoVita orchestrates workflows."
Layer 2
Rosalie AI
Model-agnostic intelligence engine. Ranked recommendations with CI, reasoning
chains, Δ(t) deviation learning. Independently deployable.
"Rosalie AI generates decision intelligence."
Layer 3
ViroVira Token (VVT)
Provider coordination & incentive layer on XRPL. Earned only on positive outcomes.
Not a payment token — fees in USDC/fiat.
"VVT aligns incentives with outcomes."
Competitive Position
No existing platform has this combination
| Capability | RoVita | EHRs | Watson † | Flatiron/Tempus | VBC Platforms |
|---|---|---|---|---|---|
| Real-time patient-specific AI recs | ✓ | ✗ | ✗ | ✗ | ✗ |
| Confidence intervals + reasoning chain | ✓ | ✗ | ✗ | ✗ | ✗ |
| Mandatory physician approval | ✓ Hardcoded | N/A | Partial | N/A | N/A |
| Continuous AI learning (Δ(t)) | ✓ Patent pending | ✗ | ✗ (failure cause) | ✗ | ✗ |
| Outcome-linked provider incentives | ✓ VVT / XRPL | ✗ | ✗ | ✗ | Financial only |
| Fee only on positive outcomes (3%) | ✓ First in class | ✗ | ✗ | ✗ | ✗ |
| On-chain performance verification | ✓ XRPL | ✗ | ✗ | ✗ | ✗ |
† Watson for Oncology discontinued 2022. $4B invested. Failure cause: no closed loop.
Intellectual Property
The RoVita platform architecture — specifically the combination of S(t) unified
patient state, Δ(t) continuous outcome learning, model-agnostic Rosalie AI,
and outcome-linked VVT incentives as an integrated integrated system — is the
subject of a patent application currently pending.
Confidentiality
This material is strictly confidential and proprietary to RoVita Inc.
It may not be reproduced, distributed, or disclosed to any third party
without the prior written consent of RoVita Inc. By accessing this platform
you acknowledge and agree to these terms.
RoVita™ v2.4.0 · rovita.io · Powered by Rosalie AI
· ViroVira Token (VVT) on XRPL · © 2026 RoVita Inc.
All rights reserved. Patent pending.
CONFIDENTIAL · NOT FOR DISTRIBUTION